Device and method for measuring concentration and distribution of human brain boron-containing drug

Abstract

The invention relates to a device and a method for measuring the concentration and distribution of a human brain boron-containing drug. The device mainly comprises a main magnetic field coil, a gradient coil, a radio frequency coil and a control and data processing system, wherein the main magnetic field coil is formed by winding a superconducting wire, and the control and data processing system comprises a computer for controlling and processing data of each part, and a spectrometer, a transceiver converter and a plurality of power amplifiers which are controlled by the computer. The method comprises the following steps: detecting deexcitation signals of hydrogen atoms and boron atoms by utilizing a nuclear magnetic resonance detection principle; obtaining corresponding spatial distribution image data; carrying out boron atom deexcitation signal calibration by using a standard boron compound die body with known concentration; and performing registration fusion on the boron atom spatial distribution image data and the human anatomy image data to obtain quantitative image data of the boron atom concentration in a human anatomy image so as to provide related basic data for making a BNCT treatment plan or other applications.

Description

technical field [0001] The invention relates to a device and method for measuring the concentration and distribution of boron-containing drugs in the human brain, which can be used to obtain boron-containing ( 10 B) The distribution and concentration information of drugs in the body, providing relevant basic data for the formulation of treatment plans (TPS), and can also be used for monitoring the distribution and concentration information of boron-containing drugs for other purposes. Background technique [0002] BNCT can treat tumors precisely at the micron level, so the distribution and concentration of boron-loaded drugs in the treatment target area must be determined before treatment, and compared with the expected distribution of the treatment plan, in order to achieve efficient treatment and protection of tumors. normal tissue. If the quantitative distribution information of boron drugs cannot be obtained before BNCT treatment, it will lead to the uncertainty of the ...

AI Technical Summary

Problems solved by technology

[0004] Among them, the method based on the measurement of boron-containing drug concentration in blood has two disadvantages: one is that the measurement time is long, and the measured boron-containing drug concentration cannot represent the concentration of boron-containing drug during treatment; The ratio is calculated on the assumption that the ratio is a fixed value, but in fact, the tumor blood ratio varies with the individual patient, with the type / location of the tumor, with the location of the tumor, and with time. The method of uniformly assuming a fixed value is too much extensive

[0005] The methods based on radiolabeled boron-containing drugs have the following problems: (1) the availability of radiolabeled boron-containing drugs; (2) the certainty of the proportion of radiolabeled boron-containing drugs in the total boron-containing drugs; (3) the increase in Drug cost; (4) The extra dose of radiopharmaceuticals to patients; (5) The spatial resolution of nuclear medicine methods is low; (6) None of them have passed the approval of drug regulatory authorities

[0006] There are several problems in the method of labeling boron-containing drugs based on MRI-sensitive elements: (1) availability of boron-containing drugs labeled with MRI-sensitive elements; (2) increased drug costs

[0007] The above problems have substantially hindered the practical application and application effect of these methods

Images